Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3077227 | 0.86 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL1897557 | 0.84 | RAB9A (0.52) | ALDH1A1CYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL1900261 | 0.83 | ALDH1A1 (0.61) | ALDH1A1MAPTNPSR1MAPK1MEN1 | |
| SCHEMBL3077801 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MAPTNPSR1MAPK1KDM4E | |
| SCHEMBL1901778 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MAPTNPSR1MAPK1RAB9A | |
| SCHEMBL1902320 | 0.80 | ALDH1A1 (0.55) | ALDH1A1MAPTHPGDRAB9AKDM4E | |
| SCHEMBL1902152 | 0.79 | ALDH1A1 (0.49) | ALDH1A1MAPTNPSR1MAPK1MEN1 | |
| SCHEMBL7739182 | 0.74 | ALDH1A1 (0.48) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL283629 | 0.66 | ALDH1A1 (0.62) | ALDH1A1MAPTNPSR1MAPK1MEN1 | |
| SCHEMBL4490129 | 0.62 | GRN (0.78) | ALDH1A1MAPTNPSR1MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | claimed |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7790761-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2010-09-07 | — | — | US | disclosed |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7405235-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405235-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | GARTHWAITE GITI | 2006-05-11 | — | — | US | disclosed |
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | disclosed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | ALDH1A1 1123/4885CYP1A2 2320/4885CYP3A4 1542/4885 |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | ALDH1A1 3948/4885CYP1A2 3557/4885CYP3A4 2352/4885 |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | CACNA1I, CACNA1F, CACNA1C | ALDH1A1 1193/4885CYP1A2 2317/4885CYP3A4 1590/4885 |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JUN, CREBBP, TFEB | ALDH1A1 3948/4885CYP1A2 3557/4885CYP3A4 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.